CoChat
Sign Up
Cited by 49

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

APOE ε4 allele elevates the expressions of inflammatory factors and promotes Alzheimer’s disease progression: A comparative study based on Han and She populations in the Wenzhou area

Fan, Yin-Ying, Cai, Qiao-Le, Gao, Zhi-Yong, Lin, Xue, Huang, Qi, Tang, Wei, Liu, Jia-Hong·2017·Brain Research Bulletin
DOI 10.1016/j.brainresbull.2017.04.017
Open this paper in CoChat — free account

Abstract

Objective This study aimed to investigate the impact of apolipoprotein E 4 (APOE4) gene polymorphisms on the expressions of inflammatory factors and the progression of Alzheimer's disease (AD). Methods A total of 185 AD patients (the case group, 130 cases from the Han ethnic group and 55 cases from the She ethnic group) and 190 healthy individuals (the control group, 130 cases from the Han ethnic group and 60 cases from the She ethnic group) were recruited for our study. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was conducted to detect APOE4 genotype and allele frequency. Enzyme-linked immunosorbent assay (ELISA) was used to determine the expressions of inflammatory factors in plasma. Results In both Han and She populations, the frequency of ε3/4 and ε4/4 genotypes and the ε4 allele was significantly higher in the case group than that in the control group. ε3/4 and ε4/4 genotypes and the ε4 allele were the risk factors for AD. In both Han and She populations, the ε2/4, ε3/4 and ε4/4 carriers showed increased levels of TNF-α, IL-6, and IL-1β when compared with the ε2/2 + ε2/3 + ε3/3 carriers. The TNF-α, IL-6, and IL-1β levels were higher in the ε4/4 carriers than those in the ε2/4 and ε3/4 carriers, and ε2/4, ε3/4 and ε4/4 carriers in the case group exhibited increased levels of TNF-α, IL-6, and IL-1β when compared with the control group (P Conclusions The APOE4 ε4 allele may enhance susceptibility to AD and promotes the expressions of infla…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.brainresbull.2017.04.017

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 24

  1. Alzheimer's, 2014, 2014 Alzheimer's disease facts and figures, Alzheimers Dement., 10, e47
  2. Alzheimer's, 2015, 2015 Alzheimer's disease facts and figures, Alzheimers Dement., 11, 332, 10.1016/j.jalz.2015.02.003 · DOI
  3. Ashford, 2004, APOE genotype effects on Alzheimer's disease onset and epidemiology, J. Mol. Neurosci., 23, 157, 10.1385/JMN:23:3:157 · DOI
  4. Ballard, 2011, Alzheimer's disease, Lancet, 377, 1019, 10.1016/S0140-6736(10)61349-9 · DOI · Paper page
  5. Candore, 2010, Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications, Rejuvenation Res., 13, 301, 10.1089/rej.2009.0993 · DOI
  6. Cova, 2016, Body mass index predicts progression of mild cognitive impairment to dementia, Dement. Geriatr. Cogn. Disord., 41, 172, 10.1159/000444216 · DOI
  7. Cruchaga, 2012, Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease, Hum. Mol. Genet., 21, 4558, 10.1093/hmg/dds296 · DOI · Paper page
  8. Di Bona, 2009, Systematic review by meta-analyses on the possible role of TNF-alpha polymorphisms in association with Alzheimer's disease, Brain Res. Rev., 61, 60, 10.1016/j.brainresrev.2009.05.001 · DOI
  9. Fernandez-Funez, 2015, Modeling the complex pathology of Alzheimer's disease in Drosophila, Exp. Neurol., 274, 58, 10.1016/j.expneurol.2015.05.013 · DOI · Paper page
  10. Forlenza, 2009, Increased serum IL-1beta level in Alzheimer's disease and mild cognitive impairment, Dement. Geriatr. Cogn. Disord., 28, 507, 10.1159/000255051 · DOI
  11. Giau, 2015, Role of apolipoprotein E in neurodegenerative diseases, Neuropsychiatr. Dis. Treat., 11, 1723, 10.2147/NDT.S84266 · DOI
  12. Gupta, 2011, Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging, Neurology, 76, 1091, 10.1212/WNL.0b013e318211c352 · DOI · Paper page
  13. Lee, 2010, Inflammation and Alzheimer's disease, Arch. Pharm. Res., 33, 1539, 10.1007/s12272-010-1006-7 · DOI · Paper page
  14. Licastro, 2007, Genetic risk profiles for Alzheimer's disease: integration of APOE genotype and variants that up-regulate inflammation, Neurobiol. Aging, 28, 1637, 10.1016/j.neurobiolaging.2006.07.007 · DOI
  15. Liu, 2013, Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy, Nat. Rev. Neurol., 9, 106, 10.1038/nrneurol.2012.263 · DOI · Paper page
  16. Liu, 2014, Apolipoprotein E gene polymorphism and Alzheimer's disease in Chinese population: a meta-analysis, Sci. Rep., 4, 4383, 10.1038/srep04383 · DOI · Paper page
  17. Lovati, 2010, APOE epsilon2 and epsilon4 influence the susceptibility for Alzheimer's disease but not other dementias, Int. J. Mol. Epidemiol. Genet., 1, 193
  18. Mahley, 2000, Apolipoprotein E: far more than a lipid transport protein, Annu. Rev. Genomics Hum. Genet., 1, 507, 10.1146/annurev.genom.1.1.507 · DOI · Paper page
  19. Raber, 2004, ApoE genotype accounts for the vast majority of AD risk and AD pathology, Neurobiol. Aging, 25, 641, 10.1016/j.neurobiolaging.2003.12.023 · DOI · Paper page
  20. Ringman, 2012, Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype, Arch. Neurol., 69, 757, 10.1001/archneurol.2012.277 · DOI
  21. Rubio-Perez, 2012, A review: inflammatory process in Alzheimer's disease, role of cytokines, ScientificWorldJournal, 2012, 756357, 10.1100/2012/756357 · DOI
  22. Vitek, 2009, APOE genotype-specific differences in the innate immune response, Neurobiol. Aging, 30, 1350, 10.1016/j.neurobiolaging.2007.11.014 · DOI · Paper page
  23. Xu, 2016, Biomarkers for early diagnostic of mild cognitive impairment in type-2 diabetes patients: a multicentre, retrospective, nested case-control study, EBioMedicine, 5, 105, 10.1016/j.ebiom.2016.02.014 · DOI
  24. Yu, 2013, APOE epsilon4, Alzheimer's disease pathology, cerebrovascular disease, and cognitive change over the years prior to death, Psychol. Aging, 28, 1015, 10.1037/a0031642 · DOI

Cited by

Sorted by citations

See all 49

Metadata

Authors
Fan, Y.-Y., Cai, Q.-L., Gao, Z.-Y., Lin, X., Huang, Q., Tang, W., & Liu, J.-H.
Venue
Brain Research Bulletin
Publisher
Elsevier BV
Published
2017-06
Volume
132
Pages
39-43
ISSN
0361-9230
DOI
10.1016/j.brainresbull.2017.04.017
Cited by
49
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review